A Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of DT2-SCT in Subjects With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

Also called NCT06789302

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Global Institute of Stem Cell Therapy and Research (from the registry)
Registry
  • NCT NCT06789302
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06789302. Randomized; double masking; primary purpose treatment. Start 2025-12 (anticipated); primary completion 2028-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of DT2-SCT in Subjects With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
DT2-SCT intravenous infusion
Intervention (Other)
Placebo
Lead sponsor
Global Institute of Stem Cell Therapy and Research (class: industry)

Record details

Record id
cardio:ct-nct06789302
Content hash
fa927f2c51fd6873cd65ba035057b4aa71a08c70104227b6cdd46324a76daba9